The abstract is read at the publisher; the summary is JClub's.
Greater intraindividual eGFR variability in patients with HFrEF is linked to higher cardiovascular risk, with a hazard ratio of 1.08 per 1 mL/min/1.73 m2 increase in estimated standard deviation.
- Why it matters: It is unclear whether fluctuations in kidney function within a person predict cardiovascular death or HF hospitalization, and whether SGLT2 inhibition can modify that prognostic signal.
- What they did: In a secondary analysis of 3,492 EMPEROR-Reduced participants, a location-scale joint model related eGFR levels, longitudinal slopes, and intraindividual variability from day 28 onward to cardiovascular death or HF hospitalization. Variability tertiles used common cutoffs across empagliflozin and placebo to compare outcomes at matched variability.
- The result: Higher eGFR variability predicted worse event-free survival in both groups, while empagliflozin reduced variability (standard deviation ratio 0.93; P = 0.005) and attenuated annual eGFR decline by 1.83 mL/min/1.73 m2/year, with better event-free survival than placebo within each variability tertile.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.